tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Helius Medical Seeks FDA Approval for PoNS Device

Story Highlights
Helius Medical Seeks FDA Approval for PoNS Device

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Helius Medical Technologies ( (HSDT) ) has issued an announcement.

On September 24, 2025, Helius Medical Technologies announced side letter agreements granting one-time cash bonuses to its CEO and CFO, which will offset any future severance or bonuses. On September 25, 2025, the company filed a 510(k) submission with the FDA for the PoNS device label expansion, seeking approval for treating gait and balance deficits in chronic stroke patients. The submission, supported by data from their Stroke Registrational Program, highlights PoNS’ superior effectiveness in improving gait deficits, which could significantly impact stroke rehabilitation and patient care.

The most recent analyst rating on (HSDT) stock is a Hold with a $15.50 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.

Spark’s Take on HSDT Stock

According to Spark, TipRanks’ AI Analyst, HSDT is a Neutral.

Helius Medical Technologies faces significant financial challenges, with declining revenue and negative profitability being the most critical factors. While technical indicators show some positive momentum, the stock’s valuation is unattractive due to ongoing losses. The overall score reflects the company’s need to improve financial stability and operational efficiency.

To see Spark’s full report on HSDT stock, click here.

More about Helius Medical Technologies

Helius Medical Technologies is a leading neurotech company in the medical device field, focusing on neurologic deficits using an orally applied technology platform that enhances the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity. Their primary product is the Portable Neuromodulation Stimulator (PoNS), which is used to improve balance and gait in patients with neurologic diseases.

Average Trading Volume: 780,953

Technical Sentiment Signal: Strong Sell

Current Market Cap: $16.4M

See more data about HSDT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1